Cochrane · systematic review · CD000332
Erythropoiesis‐stimulating agents for anemia in rheumatoid arthritis
Martí‐Carvajal, AJ, Agreda‐Pérez, LH, Solà, I · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
3
No studies
4
Included studies
NR
No studies 4 · 57.1%Ungraded 0 · 0%Very low 2 · 28.6%Low 1 · 14.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Erythropoietin (subcutaneous or intravenous at varying dosages) compared to placebo for anemia in patients with rheumatoid arthritis
Population: anemia in patients with rheumatoid arthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Health‐related quality of life Erythropoietin (subcutaneous or intravenous at varying dosages) vs placebo | no estimate extracted | 3 studies · 136 participants | Very low Downgraded: risk of bias, imprecision |
Hemoglobin (Hb) level at the end of the study Erythropoietin (subcutaneous or intravenous at varying dosages) vs placebo | no estimate extracted | 2 studies · 116 participants | Low Downgraded: risk of bias, imprecision |
Fatigue Not reported Erythropoietin (subcutaneous or intravenous at varying dosages) vs placebo | no estimate extracted | NR | No studies |
Safety (Adverse events including adverse drug reaction) Erythropoietin (subcutaneous or intravenous at varying dosages) vs placebo | no estimate extracted | 1 study · 3 participants | Very low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events Erythropoietin (subcutaneous or intravenous at varying dosages) vs placebo | no estimate extracted | NR | No studies |
Withdrawals due to lack of efficacy Erythropoietin (subcutaneous or intravenous at varying dosages) vs placebo | no estimate extracted | NR | No studies |
Withdrawals due to high blood pressure Erythropoietin (subcutaneous or intravenous at varying dosages) vs placebo | no estimate extracted | NR | No studies |